Pfizer cuts enrollment for Lyme disease trial after CRO debacle

After complications with the CRO behind Pfizer's Lyme disease shot, vaccine R&D chief Annaliesa Anderson, Ph.D., says that much fewer than the planned 18,000 participants will be recruited.